SPONSORED:

Group launches seven-figure ad buy boosting vulnerable Democrats on drug prices

Group launches seven-figure ad buy boosting vulnerable Democrats on drug prices
© iStock

A Democratic group is launching $2 million in new digital ads highlighting vulnerable House Democrats’ efforts to lower drug prices. 

The ads from the group Protect Our Care illustrate how Democrats are seeking to keep their momentum going on health care after they focused on the issue in winning back the House last year.

ADVERTISEMENT
The ad buy shows that even as the impeachment inquiry into President TrumpDonald John TrumpBiden says GOP senators have called to congratulate him Biden: Trump attending inauguration is 'of consequence' to the country Biden says family will avoid business conflicts MORE gains focus, Democrats are still trying to focus on kitchen-table issues like lowering drug prices. 

The new spending will bring the ads to 10 new districts of House freshmen, on top of the 10 districts that were part of an earlier $2 million buy in September focused on pre-existing conditions. 

“Rep. Elissa SlotkinElissa SlotkinBickering Democrats return with divisions Questions swirl at Pentagon after wave of departures Overnight Defense: Another Defense official resigns | Pentagon chief says military 'remains strong' despite purge | Top contender for Biden DOD secretary would be historic pick MORE is standing up to big drug companies,” the narrator in the ad for Slotkin, a Michigan Democrat, states. “She’s fighting to give Medicare the power to negotiate with drug companies for lower prices, reducing your costs by as much as 55 percent.”

“Thank her for leading the fight to lower your drug prices,” it adds.

The 10 new districts in the campaign are those of Democratic Reps. Angie Craig (Minn.), Sharice DavidsSharice DavidsOVERNIGHT ENERGY: House Democrats push Biden to pick Haaland as next Interior secretary | Trump administration proposal takes aim at bank pledges to avoid fossil fuel financing | Wasserman Schultz pitches climate plan in race to chair Appropriations House Democrats push Biden to pick Haaland as next Interior secretary US is far from gender balance in politics despite record year for women candidates MORE (Kan.), Antonio DelgadoAntonio Ramon DelgadoMaloney vows to overhaul a House Democratic campaign machine 'stuck in the past' Rundown of the House seats Democrats, GOP flipped on Election Day Next Congress expected to have record diversity MORE (N.Y.), Lizzie Fletcher (Texas), Jared Golden (Maine), Susie LeeSuzanne (Susie) Kelley LeeMORE (Nev.), Elaine LuriaElaine Goodman LuriaChamber-endorsed Dems struggle on election night Overnight Defense: How members of the Armed Services committees fared in Tuesday's elections | Military ballots among those uncounted in too-close-to-call presidential race | Ninth US service member killed by COVID-19 Luria holds onto Virginia House seat MORE (Va.), Lucy McBathLucia (Lucy) Kay McBathMaloney vows to overhaul a House Democratic campaign machine 'stuck in the past' Record number of Black women elected to Congress in 2020 McBath wins rematch against Handel in Georgia House race MORE (Ga.), Chris PappasChristopher (Chris) Charles PappasPappas fends off challenge from ex-Trump official in NH Centrist Democrats got their COVID bill, now they want a vote Trump-backed candidate wins NH GOP primary to take on Pappas MORE (N.H.) and Susan WildSusan WildDemocratic Women's Caucus members split endorsements for House campaign chief Democratic Rep. Susan Wild wins reelection in Pennsylvania Congress must act to end US military aid to the Philippines MORE (Pa.), all of whom face potentially tough reelection races next year. 

House Democrats are planning to vote next month on their signature legislation to lower drug prices, known as H.R. 3, which would empower the secretary of Health and Human Services to negotiate lower prices for up to 250 drugs per year. 

Speaker Nancy PelosiNancy PelosiBiden backs 0B compromise coronavirus stimulus bill US records over 14 million coronavirus cases On The Money: COVID-19 relief picks up steam as McConnell, Pelosi hold talks | Slowing job growth raises fears of double-dip recession | Biden officially announces Brian Deese as top economic adviser MORE’s (D-Calif.) office has expressed hope that Trump would back the legislation, given his support for Medicare negotiating drug prices during the 2016 campaign. But Trump backed off that support in office, and the White House has recently criticized Pelosi’s bill, in favor of a somewhat more modest bipartisan measure to lower drug prices in the Senate. 

Republicans warn Pelosi’s bill would hinder the development of new cures. 

“We don’t see that happening,” Protect Our Care Chair Leslie Dach said of GOP support for the bill.

“Every statement from the president is that he opposes it,” he added. 

Campaigning on the issue could still prove effective for Democrats given the priority the public places on lowering drug prices. 

Dach said the ads are to “be sure [House Democrats] get thanked and be sure their constituents know they’re doing it.”